These Analysts Revise Their Forecasts On DexCom Following Q3 Results
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom shares fell 1.6% to trade at $73.68 on Friday.DexCom, Inc. (NASDAQ:DXCM) reported better-than-expected third-quarter results on Thursday.
德康醫療公司（納斯達克股票代碼：DXCM）於週四發佈了優於預期的第三季度業績。
DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
德康醫療報告每股45美分的季度收益，超過了分析師共識預估的43美分。季度營業收入達到99420萬美元，超過了分析師共識預估的99071萬美元，並較去年同期的97500萬美元銷售額有所增加。
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
DexCom還宣佈，首席商業官兼執行副總裁Teri Lawver將於年底退休。Lawver將繼續擔任Dexcom的特別顧問，直到2025年初，董事長、總裁兼首席執行官Kevin Sayer將在公司爲新的首席商業官進行全球搜尋的同時，負責領導商業機構。
DexCom shares fell 1.6% to trade at $73.68 on Friday.
德康醫療股價週五下跌1.6％，報73.68美元。
These analysts made changes to their price targets on DexCom following earnings announcement.
這些分析師在德康醫療發佈業績後調整了其目標價。
- Wells Fargo analyst Larry Biegelsen maintained DexCom with an Overweight and raised the price target from $80 to $90.
- Leerink Partners analyst Mike Kratky maintained DexCom with an Outperform and lowered the price target from $90 to $87.
- JP Morgan analyst Robbie Marcus maintained the stock with a Neutral and raised the price target from $75 to $85.
- Oppenheimer analyst Steven Lichtman maintained DexCom with an Outperform and lowered the price target from $115 to $105.
- RBC Capital analyst Shagun Singh maintained the stock with an Outperform and lowered the price target from $120 to $115.
- Bernstein analyst Lee Hambright maintained DexCom with an Outperform and raised the price target from $82 to $86.
- Raymond James analyst Jayson Bedford maintained DexCom with a Strong Buy and lowered the price target from $115 to $99.
- 富國銀行分析師Larry Biegelsen維持對德康醫療的買入評級，並將目標股價從80美元上調至90美元。
- Leerink合夥人分析師Mike Kratky維持對德康醫療的跑贏評級，並將目標股價從90美元下調至87美元。
- 摩根大通分析師Robbie Marcus維持了中立看法，並將目標股價從75美元上調至85美元。
- Oppenheimer分析師史蒂文·利希特曼維持德康醫療的買入評級，並將目標價從115美元下調至105美元。
- RBC Capital分析師沙甘·辛格保持該股票的買入評級，將目標價從120美元下調至115美元。
- 伯恩斯坦分析師李·漢布賴特維持德康醫療的買入評級，並將目標價從82美元上調至86美元。
- Raymond James分析師傑森·貝德福德維持德康醫療的強烈買入評級，並將目標價從115美元下調至99美元。
- How To Earn $500 A Month From Waste Management Stock Ahead Of Q3 Earnings
- 如何在Q3收益之前從廢物管理股票中賺取每月500美元
